These cf-tDNA-unique variants are targetable primarily with small molecules that inhibit PI3K/AKT/mTOR, RTK/RAS, or P53 signaling pathways (Supplementary Figure 1), all of which have been approved in other cancers and are being tested clinically in gliomas. This evidence concerns the gene MTOR and cancer.